Molecular targets of curcumin in breast cancer (Review)
- Authors:
- Xinqiang Song
- Mu Zhang
- Erqin Dai
- Yuan Luo
-
Affiliations: Department of Life Sciences, Xinyang Normal University, Xinyang, Henan 464000, P.R. China, Hospital Attached to Xinyang Normal University, Xinyang, Henan 464000, P.R. China, State Key Laboratory of Toxicology and Medical Countermeasures, Institutes of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing 100850, P.R. China - Published online on: November 19, 2018 https://doi.org/10.3892/mmr.2018.9665
- Pages: 23-29
This article is mentioned in:
Abstract
 |
 |
|
Garcia-Aranda M and Redondo M: Protein kinase targets in breast cancer. Int J Mol Sci. 18(pii): E25432017. View Article : Google Scholar : PubMed/NCBI | |
|
Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang J, Yao PP and Zhu HP: Risk factors and preventions of breast cancer. Int J Biol Sci. 13:1387–1397. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ye JC and Formenti SC: Integration of radiation and immunotherapy in breast cancer - Treatment implications. Breast. 38:66–74. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kasi PD, Tamilselvam R, Skalicka-Woźniak K, Nabavi SF, Daglia M, Bishayee A, Pazoki-Toroudi H and Nabavi SM: Molecular targets of curcumin for cancer therapy: An updated review. Tumour Biol. 37:13017–13028. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Williams GH and Stoeber K: The cell cycle and cancer. J Pathol. 226:352–364. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fulda S: Modulation of apoptosis by natural products for cancer therapy. Planta Med. 76:1075–1079. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, Gong J, Zhong Z, Xu Z, Dang Y, et al: Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med. 6:272011. View Article : Google Scholar : PubMed/NCBI | |
|
Demain AL and Vaishnav P: Natural products for cancer chemotherapy. Microb Biotechnol. 4:687–699. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan R, Hou Y, Sun W, Yu J, Liu X, Niu Y, Lu JJ and Chen X: Natural products to prevent drug resistance in cancer chemotherapy: A review. Ann N Y Acad Sci. 1401:19–27. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Messner DJ, Robinson T and Kowdley KV: Curcumin and turmeric modulate the tumor-promoting effects of iron in vitro. Nutr Cancer. 69:481–489. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hou J and Cui HL: In Vitro antioxidant, antihemolytic and anticancer activity of the carotenoids from halophilic archaea. Curr Microbiol. 75:266–271. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nabavi SM, Marchese A, Izadi M, Curti V, Daglia M and Nabavi SF: Plants belonging to the genus Thymus as antibacterial agents: from farm to pharmacy. Food Chem. 173:339–347. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang HL, Korivi M, Lin MK, Chang HC, Wu CR, Lee MS, Chen WT and Hseu YC: Antihemolytic and antioxidant properties of pearl powder against 2,2′-azobis(2-amidinopropane) dihydrochloride-induced hemolysis and oxidative damage to erythrocyte membrane lipids and proteins. J Food Drug Anal. 25:898–907. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hirapara H, Ghori V, Anovadiya A, Baxi S and Tripathi C: Effects of ethanolic extract of Jasminum grandiflorum Linn. Flowers on wound healing in diabetic Wistar albino rats. Avicenna J Phytomed. 7:401–408. 2017.PubMed/NCBI | |
|
Nomura EC, Rodrigues MR, da Silva CF, Hamm LA, Nascimento AM, de Souza LM, Cipriani TR, Baggio CH and Werner MF: Antinociceptive effects of ethanolic extract from the flowers of Acmella oleracea (L.) R.K. Jansen in mice. J Ethnopharmacol. 150:583–589. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nabavi SM, Habtemariam S, Nabavi SF, Sureda A, Daglia M, Moghaddam AH and Amani MA: Protective effect of gallic acid isolated from Peltiphyllum peltatum against sodium fluoride-induced oxidative stress in rat's kidney. Mol Cell Biochem. 372:233–239. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Fadus MC, Lau C, Bikhchandani J and Lynch HT: Curcumin: An age-old anti-inflammatory and anti-neoplastic agent. J Tradit Complement Med. 7:339–346. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Banik U, Parasuraman S, Adhikary AK and Othman NH: Curcumin: The spicy modulator of breast carcinogenesis. J Exp Clin Cancer Res. 36:982017. View Article : Google Scholar : PubMed/NCBI | |
|
Shishodia S, Sethi G and Aggarwal BB: Curcumin: Getting back to the roots. Ann N Y Acad Sci. 1056:206–217. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Aggarwal BB, Kumar A and Bharti AC: Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res. 23:363–398. 2003.PubMed/NCBI | |
|
Han X, Deng S, Wang N, Liu Y and Yang X: Inhibitory effects and molecular mechanisms of tetrahydrocurcumin against human breast cancer MCF-7 cells. Food Nutr Res. 60:306162016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu JL, Pan YY, Chen O, Luan Y, Xue X, Zhao JJ, Liu L and Jia HY: Curcumin inhibits MCF-7 cells by modulating the NF-κB signaling pathway. Oncol Lett. 14:5581–5584. 2017.PubMed/NCBI | |
|
Zheng J, Zhou Y, Li Y, Xu DP, Li S and Li HB: Spices for prevention and treatment of cancers. Nutrients. 8(pii): E4952016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Yu J, Cui R, Lin J and Ding X: Curcumin in treating breast cancer: A review. J Lab Autom. 21:723–731. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Imran M, Ullah A, Saeed F, Nadeem M, Arshad MU and Suleria HAR: Cucurmin, anticancer, & antitumor perspectives: A comprehensive review. Crit Rev Food Sci Nutr. 58:1271–1293. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ko EY and Moon A: Natural products for chemoprevention of breast cancer. J Cancer Prev. 20:223–231. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hossain DM, Bhattacharyya S, Das T and Sa G: Curcumin: The multi-targeted therapy for cancer regression. Front Biosci (Schol Ed). 4:335–355. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou H, Beevers CS and Huang S: The targets of curcumin. Curr Drug Targets. 12:332–347. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Huang G, Xu Z, Huang Y, Duan X, Gong W, Zhang Y, Fan J and He F: Curcumin protects against collagen-induced arthritis via suppression of BAFF production. J Clin Immunol. 33:550–557. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Schneider C, Gordon ON, Edwards RL and Luis PB: Degradation of curcumin: From mechanism to biological implications. J Agric Food Chem. 63:7606–7614. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jamil QUA, Jaerapong N, Zehl M, Jarukamjorn K and Jäger W: Metabolism of curcumin in human breast cancer cells: Impact of sulfation on cytotoxicity. Planta Med. 83:1028–1034. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Vera-Ramirez L, Perez-Lopez P, Varela-Lopez A, Ramirez-Tortosa M, Battino M and Quiles JL: Curcumin and liver disease. Biofactors. 39:88–100. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Marin E, Briceño MI, Torres A and Caballero-George C: New curcumin-loaded chitosan nanocapsules: In vivo evaluation. Planta Med. 83:877–883. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Feng T, Wei Y, Lee RJ and Zhao L: Liposomal curcumin and its application in cancer. Int J Nanomedicine. 12:6027–6044. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tamvakopoulos C, Dimas K, Sofianos ZD, Hatziantoniou S, Han Z, Liu ZL, Wyche JH and Pantazis P: Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin. Clin Cancer Res. 13:1269–1277. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Venkateswarlu S, Ramachandra MS and Subbaraju GV: Synthesis and biological evaluation of polyhydroxycurcuminoids. Bioorg Med Chem. 13:6374–6380. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nagaraju GP, Aliya S, Zafar SF, Basha R, Diaz R and El-Rayes BF: The impact of curcumin on breast cancer. Integr Biol (Camb). 4:996–1007. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Labbozzetta M, Notarbartolo M, Poma P, Maurici A, Inguglia L, Marchetti P, Rizzi M, Baruchello R, Simoni D and D'Alessandro N: Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer. Ann N Y Acad Sci. 1155:278–283. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tang H, Murphy CJ, Zhang B, Shen Y, Van Kirk EA, Murdoch WJ and Radosz M: Curcumin polymers as anticancer conjugates. Biomaterials. 31:7139–7149. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Catania A, Barrajón-Catalán E, Nicolosi S, Cicirata F and Micol V: Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Cancer Res Treat. 141:55–65. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bayet-Robert M and Morvan D: Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcumin alone and in association with docetaxel. PLoS One. 8:e579712013. View Article : Google Scholar : PubMed/NCBI | |
|
Patil S, Choudhary B, Rathore A, Roy K and Mahadik K: Enhanced oral bioavailability and anticancer activity of novel curcumin loaded mixed micelles in human lung cancer cells. Phytomedicine. 22:1103–1111. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Frouin I, Montecucco A, Biamonti G, Hübscher U, Spadari S and Maga G: Cell cycle-dependent dynamic association of cyclin/Cdk complexes with human DNA replication proteins. EMBO J. 21:2485–2495. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
John PC, Mews M and Moore R: Cyclin/Cdk complexes: Their involvement in cell cycle progression and mitotic division. Protoplasma. 216:119–142. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Villegas SL, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner BM, Lederer B, et al: Expression of cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 168:179–187. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lamb R, Lehn S, Rogerson L, Clarke RB and Landberg G: Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle. 12:2384–2394. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Peurala E, Koivunen P, Haapasaari KM, Bloigu R and Jukkola-Vuorinen A: The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res. 15:R52013. View Article : Google Scholar : PubMed/NCBI | |
|
Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S and Sethi G: Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol. 73:1024–1032. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA Jr, Suman VJ, Hunt KK, Moulder SL and Keyomarsi K: Cytoplasmic cyclin E mediates resistance to aromatase inhibitors in breast cancer. Clin Cancer Res. 23:7288–7300. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mazumder S, DuPree EL and Almasan A: A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets. 4:65–75. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, et al: Cyclin E and survival in patients with breast cancer. N Engl J Med. 347:1566–1575. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Choudhuri T, Pal S, Das T and Sa G: Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem. 280:20059–20068. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al: Mutational landscape and significance across 12 major cancer types. Nature. 502:333–339. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Muller PA and Vousden KH: Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Fan H, Liang Y, Jiang B, Li X, Xun H, Sun J, He W, Lau HT and Ma X: Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells. Oncol Rep. 35:2651–2656. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Choudhuri T, Pal S, Agwarwal ML, Das T and Sa G: Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett. 512:334–340. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 93:1062–1074. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MS, Kang HJ and Moon A: Inhibition of invasion and induction of apoptosis by curcumin in H-ras-transformed MCF10A human breast epithelial cells. Arch Pharm Res. 24:349–354. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ono M, Higuchi T, Takeshima M, Chen C and Nakano S: Differential anti-tumor activities of curcumin against Ras- and Src-activated human adenocarcinoma cells. Biochem Biophys Res Commun. 436:186–191. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ettl T, Schwarz-Furlan S, Haubner F, Müller S, Zenk J, Gosau M, Reichert TE and Zeitler K: The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol. 48:822–830. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chen WC, Lai YA, Lin YC, Ma JW, Huang LF, Yang NS, Ho CT, Kuo SC and Way TD: Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells. J Agric Food Chem. 61:11817–11824. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 8:187–198. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Akkoc Y, Berrak Ö, Arisan ED, Obakan P, Çoker-Gürkan A and Palavan-Ünsal N: Inhibition of PI3K signaling triggered apoptotic potential of curcumin which is hindered by Bcl-2 through activation of autophagy in MCF-7 cells. Biomed Pharmacother. 71:161–171. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yu S, Shen G, Khor TO, Kim JH and Kong AN: Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther. 7:2609–2620. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zou YF, Xie CW, Yang SX and Xiong JP: AMPK activators suppress breast cancer cell growth by inhibiting DVL3-facilitated Wnt/β-catenin signaling pathway activity. Mol Med Rep. 15:899–907. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pohl SG, Brook N, Agostino M, Arfuso F, Kumar AP and Dharmarajan A: Wnt signaling in triple-negative breast cancer. Oncogenesis. 6:e3102017. View Article : Google Scholar : PubMed/NCBI | |
|
Kwon YJ, Leibovitch BA, Bansal N, Pereira L, Chung CY, Ariztia EV, Zelent A, Farias EF and Waxman S: Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells. Oncotarget. 8:88421–88436. 2016.PubMed/NCBI | |
|
Ma X, Zhao X, Yan W, Yang J, Zhao X, Zhang H, Hui Y and Zhang S: Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer. Cancer Biomark. 21:639–650. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Roy A, Ansari SA, Das K, Prasad R, Bhattacharya A, Mallik S, Mukherjee A and Sen P: Coagulation factor VIIa-mediated protease-activated receptor 2 activation leads to β-catenin accumulation via the AKT/GSK3β pathway and contributes to breast cancer progression. J Biol Chem. 292:13688–13701. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gao S, Ge A, Xu S, You Z, Ning S, Zhao Y and Pang D: PSAT1 is regulated by ATF4 and enhances cell proliferation via the GSK3β/β-catenin/cyclin D1 signaling pathway in ER-negative breast cancer. J Exp Clin Cancer Res. 36:1792017. View Article : Google Scholar : PubMed/NCBI | |
|
Prasad CP, Rath G, Mathur S, Bhatnagar D and Ralhan R: Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. Chem Biol Interact. 181:263–271. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Poma P, Labbozzetta M, D'Alessandro N and Notarbartolo M: NF-kB is a potential molecular drug target in triple-negative breast cancers. OMICS. 21:225–231. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pires BR, Mencalha AL, Ferreira GM, de Souza WF, Morgado-Diaz JA, Maia AM, Corrêa S and Abdelhay ES: NF-kappaB is involved in the regulation of EMT genes in breast cancer cells. PLoS One. 12:e01696222017. View Article : Google Scholar : PubMed/NCBI | |
|
Park YH: The nuclear factor-kappa B pathway and response to treatment in breast cancer. Pharmacogenomics. 18:1697–1709. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Stanic Z: Curcumin, a compound from natural sources, a true scientific challenge-a review. Plant Foods Hum Nutr. 72:1–12. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Murray-Stewart T and Casero RA: Regulation of polyamine metabolism by curcumin for cancer prevention and therapy. Med Sci (Basel). 5(pii): E382017.PubMed/NCBI | |
|
Oyagbemi AA, Saba AB and Ibraheem AO: Curcumin: From food spice to cancer prevention. Asian Pac J Cancer Prev. 10:963–967. 2009.PubMed/NCBI | |
|
Leu TH and Maa MC: The molecular mechanisms for the antitumorigenic effect of curcumin. Curr Med Chem Anticancer Agents. 2:357–370. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gafner S, Lee SK, Cuendet M, Barthélémy S, Vergnes L, Labidalle S, Mehta RG, Boone CW and Pezzuto JM: Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry. 65:2849–2859. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Qian C, Li P, Yan W, Shi L, Zhang J, Wang Y, Liu H and You Y: Downregulation of osteopontin enhances the sensitivity of glioma U251 cells to temozolomide and cisplatin by targeting the NF-κB/Bcl2 pathway. Mol Med Rep. 11:1951–1955. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shehzad A, Qureshi M, Anwar MN and Lee YS: Multifunctional curcumin mediate multitherapeutic effects. J Food Sci. 82:2006–2015. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Arablou T and Kolahdouz-Mohammadi R: Curcumin and endometriosis: Review on potential roles and molecular mechanisms. Biomed Pharmacother. 97:91–97. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Carroll CE, Ellersieck MR and Hyder SM: Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells. Menopause. 15:570–574. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Saberi-Karimian M, Katsiki N, Caraglia M, Boccellino M, Majeed M and Sahebkar A: Vascular endothelial growth factor: An important molecular target of curcumin. Crit Rev Food Sci Nutr. 1–14. 2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Chakraborty G, Jain S, Kale S, Raja R, Kumar S, Mishra R and Kundu GC: Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Rep. 1:641–646. 2008.PubMed/NCBI | |
|
DeBusk RM: Dietary supplements and cardiovascular disease. Curr Atheroscler Rep. 2:508–514. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Kawanishi S, Oikawa S and Murata M: Evaluation for safety of antioxidant chemopreventive agents. Antioxid Redox Signal. 7:1728–1739. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Di Martino RM, Luppi B, Bisi A, Gobbi S, Rampa A, Abruzzo A and Belluti F: Recent progress on curcumin-based therapeutics: A patent review (2012–2016). Part I: Curcumin. Expert Opin Ther Pat. 27:579–590. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Di Martino RMC, Bisi A, Rampa A, Gobbi S and Belluti F: Recent progress on curcumin-based therapeutics: A patent review (2012–2016). Part II: Curcumin derivatives in cancer and neurodegeneration. Expert Opin Ther Pat. 27:953–965. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, et al: Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 62:5267–5272. 2002.PubMed/NCBI | |
|
Strofer M, Jelkmann W, Metzen E, Brockmeier U, Dunst J and Depping R: Stabilisation and knockdown of HIF-two distinct ways comparably important in radiotherapy. Cell Physiol Biochem. 28:805–812. 2011. View Article : Google Scholar : PubMed/NCBI |
